TCMD

Strong BuyUnloved QualityAI neutral

Tactile Systems Technology, Inc. · Healthcare · United States · $536M cap · $5.5M/day traded

$23.64 +0.4% · close 23 Oct · scored 24 Oct

Unloved Quality: Strong and cheap; the market has not turned yet.

90
StockRank
Get score and insider alerts
Quality
83
Value
61
Momentum
47

As of 24 Oct 2026, MoatMap's StockRank for Tactile Systems Technology, Inc. (TCMD) is 90/100, ranked against 24,000+ stocks in 35 markets (Quality 83, Value 61, Momentum 47, each scored against its sector).

Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →

P/E (TTM)
21.7x
peers 27.4x
ROE
11.9%
peers -31.5%
D/E
0.1x
peers 0.2x
Dividend %
—
trailing yield
AI CONVICTION THESIS

Tactile Systems sells pneumatic compression devices for lymphedema and airway clearance, with good quality metrics and a large recent repurchase equal to about 7.6% of shares outstanding. The shares fell about 17% after second-quarter 2026 results, and the business depends on US insurer reimbursement and prescriber referrals. The buyback supports per-share value, but there is no clear evidence yet that growth is re-accelerating.

ABOUT TACTILE SYSTEMS TECHNOLOGY, INC.

Read

Tactile Systems Technology, Inc. develops and commercializes medical devices for the treatment of chronic conditions such as lymphedema and chronic venous insufficiency. The company's proprietary Flexitouch Plus and other pneumatic compression devices establish a strong market position by offering clinically proven, non-invasive solutions that improve patient outcomes. Tactile Systems operates as a specialized medical technology innovator with a direct-to-patient service model.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue246.8M274.4M293.0M329.5M10.1%350.3M362.4M396.6M9.7%
EPS-0.891.240.710.83-18.2%1.091.161.4532.2%
Shares20.3M23.6M23.9M22.4M+10.8%22.7M———
Debt72.2M50.4M45.1M16.0M-39.5%14.4M———
Equity121.4M193.6M216.6M218.9M21.7%————
Op CF5.2M35.9M40.7M42.8M101.8%30.6M———
Inv CF-1.9M-2.5M-2.5M-2.5M—————
Fin CF-9.6M5.7M-4.8M-51.2M—————
Loading 1Y...
PRICE (1Y) · USD+4.7%
21.722.222.723.223.614 Sep5 Oct23 Oct
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsVery bumpy

Swung more than 77% of stocks we rank over the past year (63% a year).

How this is worked out

StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$23.64
RSI (14)
62.4
52-Week Range-37.4% from high
Low $14.79High $37.77

SCORE BREAKDOWN

Quality
83
ROIC
16.1%82.5
ROE
11.9%74.8
GP/Assets
98.2%98.3
Op. Margin
8.0%59.0
FCF/Assets
15.6%93.7
Piotroski
893.7
Int. Cover
50.0x89.5
D/E Ratio
0.06x68.7
Current Ratio
4.12x67.1
Value
61
P/E (TTM)
21.7x56.2
EV/EBITDA
11.5x64.4
P/FCF
12.6x76.5
P/B
2.4x53.5
P/S
1.5x75.7
Div Yield
—N/A
Momentum
47
52W High %
63%44.1
RS 6M
-13%46.6
SMA 50/200
0.87x26.3
EPS Rev 4W
0.0%51.5
EPS Rev 12W
-3.3%21.4
EPS Improve
+33%44.9
Q Growth
142%87.5

FUNDAMENTALS

Market Cap
$536M
P/E (Forward)
16.2x
Gross Margin
76.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TCMD are excluded.

TickerCompanyMkt CapStockRankSignal
TCMDTactile Systems Technology, Inc.(you)$536M90Strong Buy
VMDViemed Healthcare, Inc.$373M88Strong Buy
DCTHDelcath Systems, Inc.$500M78Buy
BVSBioventus Inc.$1.0B96Strong Buy
VREXVarex Imaging Corporation$782M76Buy
CNMDCONMED Corporation$1.5B92Strong Buy
ELMDElectromed, Inc.$219M83Strong Buy
IRMDIRADIMED CORPORATION$1.1B75Buy
INSPInspire Medical Systems, Inc.$2.1B82Strong Buy
UFPTUFP Technologies, Inc.$2.3B80Strong Buy

Peer medians: ROE -31.5% · P/E 27.4x · Gross margin 62.6%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Tactile Systems Technology, Inc. (TCMD): Stock Score Summary

Tactile Systems Technology, Inc. (TCMD) has a MoatMap StockRank of 90/100 based on Quality (83/100), Value (61/100), and Momentum (47/100) factor scores. The current signal is STRONG BUY. Tactile Systems sells pneumatic compression devices for lymphedema and airway clearance, with good quality metrics and a large recent repurchase equal to about 7.6% of shares outstanding. The shares fell about 17% after second-quarter 2026 results, and the business depends on US insurer reimbursement and prescriber referrals. The buyback supports per-share value, but there is no clear evidence yet that growth is re-accelerating.

Tactile Systems Technology, Inc. develops and commercializes medical devices for the treatment of chronic conditions such as lymphedema and chronic venous insufficiency. The company's proprietary Flexitouch Plus and other pneumatic compression devices establish a strong market position by offering clinically proven, non-invasive solutions that improve patient outcomes. Tactile Systems operates as a specialized medical technology innovator with a direct-to-patient service model.

Key Financial Metrics

Price$23.64
Market Cap$536M
P/E (TTM)21.69
P/E (Forward)16.25
Price/Book2.40
Return on Equity11.9%
Return on Invested Capital16.1%
Debt/Equity0.06x
Gross Margin76.8%
Operating Margin8.0%
Revenue Growth8.6%
Free Cash Flow$43M

Tactile Systems Technology, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Tactile Systems Technology, Inc.’s (TCMD) StockRank?
MoatMap’s StockRank for Tactile Systems Technology, Inc. (TCMD) is 90/100, with a Strong Buy signal. It is a composite of Quality (83), Value (61), and Momentum (47), each scored against its sector. The composite is then ranked across MoatMap’s universe of 24,000+ stocks.
Does Tactile Systems Technology, Inc. have an economic moat?
Tactile Systems Technology, Inc. (TCMD) has a Quality factor score of 83/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Tactile Systems Technology, Inc. a buy, hold, or sell?
MoatMap’s current signal for Tactile Systems Technology, Inc. (TCMD) is Strong Buy, based on a StockRank of 90/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Tactile Systems Technology, Inc. in?
Tactile Systems Technology, Inc. (TCMD) operates in the Healthcare sector, specifically the Medical Devices industry (United States).